French pharmaceutical giant Sanofi has officially agreed to acquire Blueprint Medicines Corp. for a significant sum of $9.1 billion. This move aligns with Sanofi’s strategy to bolster its presence in the field of rare immunological diseases. The announcement was made by Bloomberg on June 2, 2025. Under the terms of the agreement, Sanofi will pay an attractive $129 per share in cash for the US-based biotech firm, reflecting a notable 27 percent premium from Blueprint’s stock price just last week.
In a sharp market reaction, shares of Blueprint Medicines surged to $128.15 in premarket trading on Nasdaq, which is a jump of 26.41 percent from a previous closing of $101.35, according to Marketwatch data. By acquiring Blueprint, Sanofi aims to emerge as a leader in immunology, expanding its portfolio to include a pipeline of experimental treatments for immunological conditions, alongside an already available drug for systemic mastocytosis, a rare illness.
Paul Hudson, CEO of Sanofi, emphasized the company’s potential for growth through further acquisitions, indicating, “Sanofi still retains a sizable capacity for further acquisitions.” This acquisition marks a pivotal moment for Sanofi, particularly as it is the largest deal the company has made since acquiring Bioverativ Inc., a Biogen Inc. spin-off, back in 2018. The largest deal in recent pharmaceutical history remains Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies.
However, not all experts are entirely optimistic. Sarita Kapila from Morgan Stanley expressed concerns in an analyst report, noting, “We see synergies with Sanofi’s existing rare-disease footprint, but expect investors to question valuation and confidence in the remaining internal R&D offering.”
On the same day as the announcement, trading for Sanofi shares dipped by 1.46 percent to 86.24 euros, down from 87.52 euros from the prior market close. In addition to the acquisition price, Blueprint shareholders will benefit from a non-tradable contingent value right, conditioned upon future development and regulatory successes, valued at $2 to $4 per right. Including these potential payments, the total transaction value could reach nearly $9.5 billion.
The acquisition is projected to be completed by the third quarter of 2025. Sanofi also stated that this major deal will not affect its financial guidance for the year.